News
Mirziyoyev: It is better to use advanced programs in pharmaceuticals and train our own personnel
The head of the republic visited the innovative scientific and production pharmaceutical cluster "Tashkent Pharma Park".TASHKENT, December 19 - Sputnik. It is better to use advanced programs in pharmaceuticals and train our own specialists than to pay foreigners and depend on them, said Shavkat Mirziyoyev during a visit to the innovative scientific and production pharmaceutical cluster "Tashkent Pharma Park". This was reported by the press service of the President of Uzbekistan.
The Pharmaceutical Technical University will become part of the cluster. It will have a pharmacopoeial center, a library, a sports complex, housing for teachers and foreign specialists. It will train highly qualified personnel in the areas of industrial pharmacy, biomedicine, biochemistry, biotechnology, biopharmaceuticals and pharmaceutical chemistry. For this purpose, training will be organized based on international programs, and laboratories of microbiology, biotechnology, cell biology, pharmacology and analytical chemistry will be opened. Graduates of the university will be awarded international diplomas from Yonsei University (South Korea), Sunderland and De Montfort (United Kingdom). In addition, scientific cooperation has been established with the universities of Dundee, Busan and Purdue.
The university has already accepted its first students this academic year.
"We attract investors from developed countries. How do they evaluate Uzbekistan? Through communication with you. The main wealth of our country is youth! It is better to use advanced programs in pharmaceuticals and train our own specialists than to pay foreign specialists and depend on them. That is why we are creating a new university and introducing dual education. Here you will be able to get not only theoretical knowledge, but also consolidate it in practice.
Mirziyoyev emphasized in a conversation with student youth.
Then the head of the republic got acquainted with the activities of the logistics center "Grand Pharm Logistics Hub" in the Zangiata district of the Tashkent region.
The hub is located on the territory of the innovative cluster "Tashkent Pharma Park" and occupies an area of 10 hectares.
As part of the project worth $ 40 million, a three-story administrative building, warehouses, a hotel, a canteen and a hostel were built here. More than 300 jobs were created.
The area of warehouse premises is 50 thousand square meters. The center can receive, store and distribute large batches pharmaceutical products in accordance with international standards. All processes are fully digitalized.
The logistics center will also become an important support for other manufacturers included in the Tashkent Pharma Park cluster. It provides storage and export services for products through the international SAP system. There are GDP and GSP certificates, licenses for customs warehouses and international transportation.
To comply with high quality standards, air cooling systems were installed here, which ensure a stable temperature even during cargo loading. The center also provides transportation services with more than 20 trucks, for which parking and technical maintenance are organized.
To date, logistics links have been established with Russia, Kazakhstan, Turkmenistan, Kyrgyzstan, Germany, Poland, France, Hungary, Romania and Turkey. The geography of cooperation continues to expand.
The President instructed the responsible persons to facilitate the simplification of storage and registration processes for products, reduction of costs and increase in the availability of drugs.
The dialogue has continued with the heads of pharmaceutical companies.
The head of the republic put forward a number of initiatives to localize production and expand exports.
Asakabank and the Agency for the Development of the Pharmaceutical Industry, together with large enterprises, will develop a program until 2025 to develop and produce 200 popular types of drugs, which will double the volume of production. $400 million, raised on preferential terms, will be allocated for the implementation of such projects.
An Investment Fund for Advanced Pharmaceutical Projects will be created, which will become a shareholder and catalyst for projects in such areas as biopharmaceuticals, cell technologies and oncology.
The Reconstruction and Development Fund will open a $100 million credit line for Asakabank for projects in the field. These funds will also be issued for leasing services.
Asakabank will also open a venture company with a capital of $10 million to finance start-ups and commercialize new developments. Companies can allocate additional funds without expertise in an amount equal to the amount of independently attracted investments.
In addition, it was determined that 20 billion soums will be allocated from the Innovation Fund in the form of grants to support new developments. These funds are intended to transform new domestic drug developments into commercial projects and support startups.
The term of customs benefits for local pharmaceutical enterprises, which ends on January 1, 2025, will be extended for another three years.
It was also discussed that domestic enterprises are ready to produce drugs using the technology and recipes of leading foreign pharmaceutical companies. However, there is no necessary legal framework for such cooperation; each such drug must be clinically tested and registered as a new product. This takes a lot of time. In this regard, Mirziyoyev noted the importance of simplifying this procedure.
In order to expand exports, the costs of entrepreneurs to obtain certificates from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) will be covered by the budget.
“The country is developing the sphere of production of substances and cosmetic components of plant origin. To support this work, within the framework of Asakabank projects, next year plantations of 5 hectares will be created for each type of medicinal plant and 5 pilot projects for their processing will be implemented."
the report says.
In general, it has been determined that a portfolio of projects worth a total of $1 billion will be formed in the pharmaceutical industry. They will be aimed at ensuring the quality of the most popular drugs at a level not inferior to foreign analogues, increasing competition and increasing the affordability of prices.